
News|Articles|December 1, 2006
FDA Actions in Brief (December 2006)
Imatinib (Gleevec, Novartis) was approved for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers highlight DR-70 as a possible biomarker for early bladder cancer detection
2
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
3
FDA approves Poherdy, first biosimilar of Perjeta, to treat HER-positive breast cancer
4
Cogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.
5


















































